Currently our work concentrates on ricin chain A inhibitors, intended as post-exposure treapeutics against ricin poisoning. Several of our compounds exhibit in vitro activity in the low nanomolar range.
Image: structure of Ricin chain A/formycin complex, based on PDB 1IFU entry.